Article 61: Why Class I devices still fail clinical evaluation

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

The confusion around Article 61 of the MDR is more common than it should be. Even experienced regulatory teams sometimes misinterpret what clinical evaluation means for their device class. They assume that lower risk means lower documentation. That is not what the regulation says.

Article 61 does not give exemptions. It defines the clinical evaluation requirement across all device classes. The regulation is explicit: every manufacturer must demonstrate conformity with relevant general safety and performance requirements through clinical evaluation. The scope of that evaluation depends on the device, not on whether the manufacturer finds it convenient.

Let me walk through what Article 61 actually requires, what it means in practice, and where manufacturers consistently go wrong.

What Article 61 Actually States

Article 61(1) states that clinical evaluation must be planned, conducted, and documented for all devices. The manufacturer must demonstrate that the device meets the general safety and performance requirements under normal conditions of use, and that the benefit-risk ratio is acceptable.

This applies to Class I, Class IIa, Class IIb, and Class III devices. There is no opt-out clause. There is no statement that says literature alone is sufficient for low-risk devices. The regulation requires clinical evaluation, and that evaluation must follow a defined methodology.

Article 61(3) references Annex XIV, which describes the structure and content of the clinical evaluation. Annex XIV Part A outlines the methodology. It includes a clinical development plan, a clinical evaluation plan, and a clinical evaluation report. The depth and rigor scale with the risk class, but the structure does not disappear.

How Requirements Scale Across Device Classes

The regulation does not provide a checklist that says Class I devices need X pages and Class III devices need Y pages. It provides a framework that must be applied proportionately. That proportionality is based on risk, novelty, and the nature of the claims.

For a Class I non-sterile, non-measuring device with a well-established design and clear equivalence to existing products, the clinical evaluation may rely primarily on literature and performance data. But that does not mean the manufacturer can submit a five-page summary and call it sufficient. The CER must still demonstrate that the literature search was systematic, that the selected data are relevant, and that the appraisal was rigorous.

For a Class IIa device, the same principles apply, but the expectations increase. The literature must cover clinical outcomes, not just technical performance. The equivalence claim must be detailed and justified. If the device has novel features or is used in a sensitive application, clinical data may be required even if the risk class is moderate.

For Class IIb and Class III devices, clinical investigations are generally expected unless robust equivalence can be demonstrated. Annex XIV Part A, Section 3 makes this clear. If the device is implantable, supports or sustains life, or has a high-risk profile, the burden of proof shifts. Literature alone is rarely sufficient.

What Proportionality Actually Means

Proportionality is frequently misunderstood. It does not mean less effort. It means appropriate effort based on the risk and the claims. A Class I device with a simple, well-known design still requires a CER. The evaluation may be shorter, but it must be complete.

I have seen manufacturers submit Class I CERs that consist of a literature search with no appraisal, no analysis, and no conclusion. The document lists studies but does not explain how those studies support the device’s safety or performance. This does not meet the requirement of Article 61.

Proportionality also applies to post-market clinical follow-up. Article 61(11) requires that the clinical evaluation is updated throughout the lifetime of the device using data from PMCF. For a Class I device, PMCF may be based on complaint data, vigilance reports, and literature monitoring. For a Class III device, PMCF often includes active data collection from registries or studies.

The regulation allows flexibility in how you collect evidence. It does not allow flexibility in the requirement to collect evidence.

The Role of Equivalence in Article 61 Compliance

Article 61(5) allows clinical evaluation to be based on equivalence to other devices if certain conditions are met. This is where many manufacturers make their biggest mistake. They assume that declaring equivalence is enough. It is not.

The regulation requires that the manufacturer demonstrate equivalence through technical, biological, and clinical characteristics. The devices must have the same intended purpose, similar technology, and comparable performance. The evidence must be detailed and documented.

MDCG 2020-5 provides guidance on this. It describes the three-step approach: technical equivalence, biological equivalence, and clinical equivalence. All three must be satisfied. If there is any difference in material, design, or indication, the equivalence claim weakens, and additional clinical data may be required.

I reviewed a submission where the manufacturer claimed equivalence to a predicate device based on similar function. The materials were different. The manufacturing process was different. The clinical data referenced did not include the same patient population. The Notified Body rejected the equivalence claim. The manufacturer then had to generate new clinical data, which delayed the project by more than a year.

When Clinical Investigations Are Required

Article 61(4) states that clinical investigations are required for implantable devices and Class III devices unless equivalence can be demonstrated. This is often interpreted too narrowly. The regulation does not limit investigations to those two categories. It simply highlights them as cases where investigations are particularly important.

A Class IIb device with a novel mechanism of action may require clinical investigation even if it is not implantable. A Class IIa device with claims that cannot be supported by literature alone may require clinical investigation. The decision is not based solely on the risk class. It is based on the sufficiency of available evidence.

MDCG 2020-13 provides guidance on clinical investigations under the MDR. It explains when investigations are necessary, how they should be designed, and what evidence they must generate. Manufacturers who assume they can avoid clinical investigations because their device is not Class III often find themselves facing major gaps during review.

What Happens When Article 61 Is Not Followed

When a manufacturer submits a clinical evaluation that does not meet Article 61 requirements, the consequences are predictable. The Notified Body issues a non-conformity. The manufacturer must revise the CER, often requiring new literature searches, new appraisals, or new clinical data. The review timeline extends. Market access is delayed.

In some cases, the deficiency is more serious. If the clinical evaluation is fundamentally incomplete, the Notified Body may suspend the review entirely. The manufacturer must start over, sometimes with a new clinical evaluation plan. This can add years to the process.

Competent authorities also review CERs during audits and post-market surveillance. If a device is on the market and the clinical evaluation is found to be insufficient, the authority can require a corrective action, suspend the certificate, or withdraw the device from the market.

These are not theoretical risks. They happen regularly. The clinical evaluation is the technical core of MDR compliance. If it is weak, everything else becomes fragile.

Practical Approach to Article 61 Compliance

Start with a clinical evaluation plan that reflects the device risk, the intended claims, and the available evidence. The plan should describe the literature search strategy, the equivalence approach if applicable, and the PMCF methodology. This is not a formality. It is the blueprint for the entire clinical evaluation.

Conduct the literature search systematically. Use defined databases, clear search terms, and transparent inclusion criteria. Document every step. The search must be reproducible. If a reviewer cannot follow your methodology, the evaluation will be questioned.

Appraise the selected studies rigorously. Do not simply list abstracts. Assess the quality of each study, the relevance to your device, and the strength of the evidence. Use a structured appraisal format. MDCG 2020-13 Annex A2 provides tables for this purpose.

Synthesize the evidence into clear conclusions. State explicitly what the data demonstrate about safety and performance. Identify any gaps. Explain how those gaps will be addressed through PMCF or additional studies. The conclusion must answer the question: does the device meet the relevant general safety and performance requirements?

Update the CER based on PMCF data. This is not optional. Article 61(11) requires it. The updated CER must reflect new evidence, new risks, and any changes to the benefit-risk profile. This is how clinical evaluation remains valid over time.

What This Means for Your Daily Work

If you are preparing a submission, do not treat the CER as a document to be checked off. Treat it as the argument that supports your entire technical file. The Notified Body will assess it in detail. The quality of your CER directly affects the speed and outcome of your review.

If you are managing a device that is already on the market, ensure the PMCF plan is active and the CER is updated regularly. Competent authorities are increasingly focused on post-market clinical data. A stale CER is a compliance risk.

If you are working with a Class I device, do not assume the requirements are minimal. Article 61 applies to you. The scope may be narrower, but the structure and rigor remain.

The regulation is clear. The expectations are high. The best way to meet them is to plan carefully, document thoroughly, and update continuously.

This is how clinical evaluation works under the MDR. It is not about minimizing effort. It is about demonstrating conformity through structured evidence. That is what Article 61 requires, and that is what reviewers expect.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.